XML 26 R10.htm IDEA: XBRL DOCUMENT v3.3.1.900
Balance Sheet Details
12 Months Ended
Dec. 31, 2015
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Details
Balance Sheet Details
Accounts Receivable
Accounts receivable consist of the following (in thousands):
 
 
December 31,
 
2015
 
2014
Accounts receivable
$
39,380

 
$
41,233

Less allowance for doubtful accounts
(1,061
)
 
(793
)
Accounts receivables, net
$
38,319

 
$
40,440



Inventories
Inventories consist of the following (in thousands):
 
 
December 31,
 
2015
 
2014
Raw materials
$
7,237

 
$
5,020

Work-in-process
1,908

 
1,032

Finished goods
55,393

 
57,020

 
64,538

 
63,072

Less reserve for excess and obsolete finished goods
(19,630
)
 
(21,325
)
Inventories, net
$
44,908

 
$
41,747



Property and Equipment
Property and equipment consist of the following (in thousands except for useful lives):
 
 
Useful lives
(in years)
 
December 31,
2015
 
2014
Surgical instruments
4
 
$
65,723

 
$
62,872

Machinery and equipment
7
 
15,520

 
15,382

Computer equipment
3
 
3,984

 
3,180

Office furniture and equipment
5
 
3,746

 
3,789

Leasehold improvements
various
 
3,856

 
3,841

Building
39
 
65

 
65

Land
n/a
 
9

 
9

Construction in progress
n/a
 
354

 
1,320

 
 
 
93,257

 
90,458

Less accumulated depreciation and amortization
 
 
(71,312
)
 
(64,418
)
Property and equipment, net
 
 
$
21,945

 
$
26,040


Total depreciation expense was $13.0 million, $12.2 million and $14.6 million for the years ended December 31, 2015, 2014 and 2013, respectively. At December 31, 2015, assets recorded under capital leases of $2.6 million were included in the machinery and equipment balance and $0.1 million are included in the construction in progress balance. At December 31, 2014, assets recorded under capital leases of $3.2 million were included in the machinery and equipment balance and $0.6 million are included in the construction in progress balance. Amortization of assets under capital leases is included in depreciation expense.
 Intangible Assets
Intangible assets consist of the following (in thousands except for useful lives):
 
 
Remaining Avg. Useful lives (in years)
 
December 31,
2015
 
2014
Developed product technology
1
 
$
21,633

 
$
22,526

Distribution rights
4
 
2,100

 
2,095

Intellectual property
 
1,004

 
1,004

License agreements
1
 
16,714

 
16,716

Core technology
4
 
4,086

 
4,554

Trademarks and trade names
2
 
3,245

 
3,559

Customer-related
9
 
19,169

 
20,493

Distribution network
5
 
4,027

 
4,027

Physician education programs
 
2,513

 
2,802

Supply agreement
 
225

 
225

 
 
 
74,716

 
78,001

Less accumulated amortization
 
 
(53,100
)
 
(47,742
)
Intangible assets, net
 
 
$
21,616

 
$
30,259


Total expense related to amortization of intangible assets was $6.1 million, $6.2 million and $11.6 million for the years ended December 31, 2015, 2014 and 2013, respectively.
In 2015, the Company determined that the physician education intangible asset acquired in the Scient’x acquisition was impaired. As a result, the Company recorded a $0.9 million expense, which is included in goodwill and intangible impairment in the year ended December 31, 2015. Prior to the impairment, amortization of the physician eduction intangible asset had been recorded in amortization of acquired intangible assets within operating expenses.
On June 19, 2015, the Company entered into an exclusive distribution agreement with a third party to market a biologic product that would replace its existing NEXoss Synthetic Bone Graft. The Company expensed $0.3 million as an impairment charge in cost of goods sold for the write-off of an intangible asset related to this product. Additionally, due to a revised marketing strategy for the Company's Epicage interbody fusion device, the Company evaluated the related intangible asset for impairment in June 2015. As a result of this impairment analysis the Company expensed $0.9 million as an impairment charge in cost of goods sold for the write-off of an intangible asset related to this product.
During 2013, the Company decided to discontinue marketing and selling of an adult stem cell product sold under the Company's private label name of PureGen and two additional products. The Company expensed $1.3 million as impairment charges in cost of goods sold in the year ended December 31, 2013 for the write-off of intangible assets related to these products.
The future expected amortization expense related to intangible assets as of December 31, 2015 is as follows (in thousands):

 
 
Year Ending December 31,
 
2016
$
4,001

2017
3,995

2018
2,844

2019
2,410

2020
1,811

Thereafter
6,555

 
 
Total
$
21,616

 
 


 Goodwill
The changes in the carrying amount of goodwill from December 31, 2014 through December 31, 2015 were as follows (in thousands):
 
 
 
 
2015
 
2014
Balance at January 1
$
171,333

 
$
183,004

Impairment charge
(164,266
)
 

Effect of foreign exchange rate on goodwill
(7,067
)
 
(11,671
)
Balance at December 31
$

 
$
171,333



Accrued Expenses
Accrued expenses consist of the following (in thousands):
 
 
December 31,
 
2015
 
2014
Commissions and sales milestones
$
5,920

 
$
6,259

Payroll and payroll related
5,577

 
8,291

Litigation settlements
4,400

 
7,393

Accrued professional fees
2,203

 
2,342

Royalties
1,578

 
2,129

Restructuring and severance accruals
1,358

 
849

Accrued taxes
1,074

 
1,344

Accrued interest
999

 
946

Other
6,682

 
5,840

Total accrued expenses
$
29,791

 
$
35,393